- Home » News and EventsPage 2
NEWS & EVENTS
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence for Cell Therapies in Gosselies, Belgium
Dec 8, 2022
The new facility will be one of the largest in the world with multi-product, segregated suites designed to support autologous and allogeneic cell therapy manufacturing.
Catalent Completes Expansion of Clinical Supply Facility in Shanghai, China
Dec 1, 2022
The project has seen the site increase by approximately 30,000 square feet, which has allowed the installation of additional refrigerated and deep-frozen storage, and secondary packaging capabilities to be expanded.
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
Nov 3, 2022
The ADC candidates have been developed using Catalent’s proprietary SMARTag® technology.
Catalent Expands Biologics Analytical Capabilities with New Laboratories at Center of Excellence in Kansas City, Missouri
Oct 20, 2022
Catalent today announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.
Catalent Appoints Karen Santiago as Vice President and Chief Accounting Officer
Sep 19, 2022
Karen will become a member of the Company’s Executive Leadership Team and serve as its principal accounting officer.
Catalent Expands Singapore Clinical Supply Facility for Increased Temperature-Controlled Capabilities
Sep 12, 2022
The investment will increase the site’s footprint by nearly 20% to 31,000 square feet, and allow the installation of 35 new freezers for ultra-low temperature (ULT) storage.
Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis® Technology
Sep 12, 2022
The agreement will focus on investigating a market-ready proprietary formulation and optimized delivery route for MDMA using Catalent’s proprietary Zydis® ODT technology.
Catalent Appoints Dr. Wai Lam Ling as Vice President, Scientific Advisory
Sep 8, 2022
Reporting to Julien Meissonnier, Catalent’s Vice President, and Chief Scientific Officer, Dr. Ling will join the company’s Science & Technology Leadership team.
Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity
Aug 9, 2022
The acquisition strengthens capabilities in integrated oral solid formulation development, manufacturing, and packaging to help customers simplify and accelerate their programs.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.